Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Annovis Bio
(NYSE:ANVS)
Intraday
$8.30
-0.01
[-0.12%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$8.30
-0.01
[-0.12%]
Last update: 8:48AM
Get Real Time Here
Get Report
Watch
Q1 2024 Earnings were released on Mon May 13th, before the market open
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Annovis Bio Stock (NYSE:ANVS)
Annovis Bio Stock (NYSE: ANVS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, May 15, 2024
Behind the Scenes of Annovis Bio's Latest Options Trends
Benzinga Insights
-
4 days ago
Tuesday, May 14, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
5 days ago
Monday, May 13, 2024
Annovis Bio shares are trading higher after the company reported better-than-expected Q1 GAAP EPS results.
Benzinga Newsdesk
-
May 13, 2024, 11:05AM
HC Wainwright & Co. Maintains Buy on Annovis Bio, Lowers Price Target to $23
Benzinga Newsdesk
-
May 13, 2024, 7:49AM
Annovis Bio's Cash And Cash Equivalents Totaled $3.1M As Of March 31, 2024, Will Fund Its Operations Into The Fourth Quarter Of 2024
Benzinga Newsdesk
-
May 13, 2024, 7:42AM
Annovis Bio Q1 2024 GAAP EPS $(0.72) Beats $(0.86) Estimate
Benzinga Newsdesk
-
May 13, 2024, 7:40AM
Thursday, May 09, 2024
Annovis Reports Completion Of Data Cleaning For Phase III Study Of Buntanetap In Patients With Early Parkinson's Disease; Topline Efficacy Data Is Expected In June
Benzinga Newsdesk
-
May 9, 2024, 7:54AM
Monday, May 06, 2024
Annovis Bio CEO Outlines Next Steps in Alzheimer's Research After Mixed Phase II/III Trial Results
Benzinga Newsdesk
-
May 6, 2024, 7:35AM
Tuesday, April 30, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Apr 30, 2024, 12:31PM
Canaccord Genuity Maintains Buy on Annovis Bio, Lowers Price Target to $26
Benzinga Newsdesk
-
Apr 30, 2024, 8:02AM
HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
Benzinga Newsdesk
-
Apr 30, 2024, 6:25AM
Monday, April 29, 2024
S&P 500 Edges Higher; ON Semiconductor Earnings Top Views
Avi Kapoor
-
Apr 29, 2024, 2:34PM
Why Is Alzheimer's-Focused Annovis Bio Stock Nosediving On Monday?
Vandana Singh
-
Apr 29, 2024, 1:53PM
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Apr 29, 2024, 1:04PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Apr 29, 2024, 12:31PM
Annovis Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Down -65.3%
Benzinga Newsdesk
-
Apr 29, 2024, 11:53AM
Annovis Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Down -63.6%
Benzinga Newsdesk
-
Apr 29, 2024, 11:36AM
Annovis Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Down -59.4%
Benzinga Newsdesk
-
Apr 29, 2024, 11:18AM
Annovis Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Down -48.1%
Benzinga Newsdesk
-
Apr 29, 2024, 10:52AM
Annovis Bio shares are trading lower after the company announced data from its Phase II/III Alzheimer study of buntanetap in mild to moderate Alzheimer's. Efficacy in the CGIC endpoint was not reached due to the limited number of patients and short trial duration.
Benzinga Newsdesk
-
Apr 29, 2024, 10:49AM
Annovis Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Down -37.8%
Benzinga Newsdesk
-
Apr 29, 2024, 10:46AM
Annovis Bio Shares Resume Trading
Benzinga Newsdesk
-
Apr 29, 2024, 10:46AM
Annovis Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Down -25.6%
Benzinga Newsdesk
-
Apr 29, 2024, 10:45AM
Annovis Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Down -14.7%
Benzinga Newsdesk
-
Apr 29, 2024, 10:36AM
Annovis Bio Shares Resume Trade
Benzinga Newsdesk
-
Apr 29, 2024, 10:35AM
Annovis Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Down -5.22%
Benzinga Newsdesk
-
Apr 29, 2024, 10:34AM
Annovis Bio Says Buntanetap Is Safe And Well Tolerated
Benzinga Newsdesk
-
Apr 29, 2024, 10:16AM
Annovis Bio Announces Statistically Significant Phase II/III Data In Patients With Early Alzheimer's Disease; Efficacy In The CGIC Endpoint Was Not Reached Due To The Limited Number Of Patients And Short Trial Duration
Benzinga Newsdesk
-
Apr 29, 2024, 10:15AM
Annovis Bio Shares Halted, News Pending
Benzinga Newsdesk
-
Apr 29, 2024, 9:49AM
Tuesday, April 02, 2024
HC Wainwright & Co. Maintains Buy on Annovis Bio, Maintains $30 Price Target
Benzinga Newsdesk
-
Apr 2, 2024, 8:56AM
Monday, April 01, 2024
Annovis Announces Publication That Supports Understanding Of Buntanetap's Mechanism Of Action In Humans
Benzinga Newsdesk
-
Apr 1, 2024, 8:07AM
Thursday, March 21, 2024
HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
Benzinga Newsdesk
-
Mar 21, 2024, 6:22AM
Wednesday, March 20, 2024
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Mar 20, 2024, 2:03PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Mar 20, 2024, 1:31PM
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
-
Mar 20, 2024, 11:41AM
Annovis Bio shares are trading higher after the company announced the completion of data cleaning for its Phase 2/3 study of Buntanetap in patients with mild to moderate Alzheimer's disease, with Topline efficacy data expected in April.
Benzinga Newsdesk
-
Mar 20, 2024, 7:40AM
Annovis Bio Announced The Completion Of Data Cleaning For Its Phase 2/3 Study Of Buntanetap In Patients With Mild To Moderate Alzheimer's Disease. Topline Efficacy Data Is Expected In April
Benzinga Newsdesk
-
Mar 20, 2024, 7:32AM
Wednesday, February 28, 2024
Brookline Capital Downgrades Annovis Bio to Hold, Announces $9 Price Target
Benzinga Newsdesk
-
Feb 28, 2024, 6:51AM
Friday, February 16, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Feb 16, 2024, 4:31PM
Wednesday, February 14, 2024
Annovis Bio Announced The Last Patient Last Visit In The Phase 2/3 Study Of Its Lead Candidate Buntanetap In Patients With Mild To Moderate Alzheimer's Disease
Benzinga Newsdesk
-
Feb 14, 2024, 7:32AM
Thursday, February 01, 2024
Annovis Bio May Offer And Sell Shares Of Common Stock, Shares Of Preferred Stock, Debt Securities, Warrants, Of Up To An Aggregate Initial Offering Price Of $250M - Filing
Benzinga Newsdesk
-
Feb 1, 2024, 4:13PM
Tuesday, January 30, 2024
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company's Portfolio
Benzinga Newsdesk
-
Jan 30, 2024, 8:14AM
Wednesday, January 24, 2024
Dow Edges Lower; US Composite PMI Rises In January
Avi Kapoor
-
Jan 24, 2024, 3:46PM
Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Jan 24, 2024, 1:05PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Jan 24, 2024, 12:31PM
Crude Oil Rises Over 1%; DuPont Shares Plunge
Avi Kapoor
-
Jan 24, 2024, 12:04PM
Why Annovis Bio (ANVS) Stock Is Getting Hammered
Henry Khederian
-
Jan 24, 2024, 11:39AM
Annovis Bio shares are trading lower after the company announced a postponement in the Phase III study data release for buntanetap in Parkinson's Disease.
Benzinga Newsdesk
-
Jan 24, 2024, 11:17AM
Dow Jumps 100 Points; Netflix Reports Strong Q4 Sales
Avi Kapoor
-
Jan 24, 2024, 9:43AM
Annovis Bio Postpones Phase III Study Data Release
Benzinga Newsdesk
-
Jan 24, 2024, 8:08AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch